Ruben A. Mesa, M.D., director of Mays Cancer Center at the newly named UT Health San Antonio MD Anderson Cancer Center, discusses the approval of fedratinib (Inrebic) in myelofibrosis and other JAK inhibitors in the treatment pipeline.
Newsroom
Ruben A. Mesa, M.D., director of Mays Cancer Center at the newly named UT Health San Antonio MD Anderson Cancer Center, discusses the approval of fedratinib (Inrebic) in myelofibrosis and other JAK inhibitors in the treatment pipeline.